Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029?
Health & MedicineOne-Off2a
Manifold MarketsSem KYCDados de resolução verificadosRazoavelmente calibradoPrevisão da comunidade atual
Sim 79.5%
Previsores
5
Tipo de pergunta
binary
Metodologia
Play-money forecasting platform
Tipo de fonte
Previsão
Dados do mercado
Atualizado há 18 horas
Desatualizado30/06/24, 16:24 UTC31/12/28, 22:59 UTC
Tendências
Mercados Relacionados
Perguntas relacionadas para dar contexto, não uma comparação de contratos equivalentes.
Will ME/CFS blood test replicate in larger study?
Manifold MarketsWill the finding of high WASF3 in ME/CFS (Hwang,PNAS, 2023) be successfully replicated by the end of 2027?
Manifold MarketsCommercially available tooth regeneration therapy
Manifold MarketsHantavirus pandemic in 2026?
PolymarketWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
KalshiFDA approves skin cancer vaccine by which date?
PolymarketRegras
In 2019 Cochrane published a review concluding graded exercise therapy (GET) was beneficial for people with ME/CFS.
- This goes against nearly every other major organisation, whom say that exercise therapy is harmful for people with ME/CFS:
- CDC (Since 2017) (US)
- NICE and NHS (since 2021) (UK)
- Mayo Clinic (Since 2024) (US)
- Australian ME/CFS Guidelines (Since 2024) (Australia)
Mercados abertos
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.2pt97%
- Yes+0.2pt3%
- Volume total
- € 15,6 mi
- Volume 24h
- € 20,3 mil
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+0.6pt4%
- Volume total
- € 1,6 mi
- Volume 24h
- € 8 mil
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+4.0pt65%
- September41%
- June28%
- Volume total
- € 84,1 mil
POLYMARKETEbola pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volume total
- € 652,6 mil
- Volume 24h
- € 3,4 mil
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-4.0pt58%
+2 mais resultados
- Volume total
- € 865,4 mil
- Volume 24h
- € 3 mil
POLYMARKETNew pandemic in 2026?
- No+1.0pt94.1%
- Yes-1.0pt5.9%
- Volume total
- € 915,2 mil
- Volume 24h
- € 1,2 mil
- When will the FDA approve Intellia Therapeutics' lonvo-z?
- Will 3 mg THC beverages be federally legal to sell?
- Measles cases in U.S. in 2026?
- Cyclosporiasis cases reported in the US in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve CagriSema?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Perguntas frequentes
- Quais são as probabilidades atuais de Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029??
- A Manifold Markets cota Yes em 80% em 8 de setembro de 2026.
- Quando Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029? é resolvido?
- Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029? deverá ser resolvido em 31 de dezembro de 2028.
- Como Will Cochrane retract their Review of Exercise Therapy for ME/CFS or publish an updated review (against GET) by 2029? é liquidado?
- A Manifold Markets liquida este mercado da seguinte forma: In 2019 Cochrane published a review concluding graded exercise therapy (GET) was beneficial for people with ME/CFS.